Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673614 · ClinicalTrials.gov registry record · NA
Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Not yet
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07673614 is a NA study that has not yet begun recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 50 participants.
The verdict
NCT07673614, a NA study, has not yet begun recruiting, sponsored by University of Michigan Rogel Cancer Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemotherapy as a result of changes to the nerves. A non-invasive form of brain stimulation called tDCS, applied to the area of the brain involved in sensation and movement, can temporarily improve the ability to detect vibration and temperature, as well as balance and walking, which may improve sensation and reduce pain in cancer survivors with CIPN.
Interventions
- OTHER Survey Administration
- DEVICE Transcranial Direct Current Stimulation
- PROCEDURE Sham Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07673614
The ClinicalTrials.gov registry entry for NCT07673614 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Survey Administration is the first listed.
NCT07673614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07673614 about?
NCT07673614 is a clinical study titled "Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors". This clinical trial tests how well a type of non-invasive brain stimulation called transcranial direct current stimulation (tDCS) works to treat chemotherapy induced peripheral neuropathy (CIPN) in cancer survivors. CIPN is numbness, tingling, pain, and movement problems that can develop after chemo...
What is the current status of trial NCT07673614?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-08-01. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07673614?
The interventions under investigation include: Survey Administration (OTHER), Transcranial Direct Current Stimulation (DEVICE), Sham Intervention (PROCEDURE).
Who is sponsoring clinical trial NCT07673614?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.